RitaNandaMD

PubMed

• Validation of the RSClin risk calculator in the National Cancer Data Base.
  Augustin G L Vannier, Asim Dhungana, Fangyuan Zhao, Nan Chen, Sarah Shubeck, Olwen M Hahn, Rita Nanda, Nora T Jaskowiak, Gini F Fleming, Olufunmilayo I Olopade, Alexan...> ;Cancer. 2024 Apr 15
• The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
  Elena Michaels, Nan Chen, Rita Nanda> ;Clinical Breast Cancer. 2024 Mar 6
• 1 citations
  Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
  Beverly Kyalwazi, Christina Yau, Michael J Campbell, Toshio F Yoshimatsu, A Jo Chien, Anne M Wallace, Andres Forero-Torres, Lajos Pusztai, Erin D Ellis, Kathy S Albain...> ;JAMA Network Open. 2023 Dec 1
• Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer.
  Zhen Ren, Federico D Pineda, Frederick M Howard, Xiaobing Fan, Rita Nanda, Hiroyuki Abe, Kirti Kulkarni, Gregory S Karczmar> ;Magnetic Resonance Imaging. 2023 Aug 21
• 1 citations
  Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients.
  Jincong Q Freeman, Sarah Shubeck, Frederick M Howard, Nan Chen, Rita Nanda, Dezheng Huo> ;NPJ Breast Cancer. 2023 May 6
• 5 citations
  The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.
  Elizabeth Terman, Jori Sheade, Fangyuan Zhao, Frederick M Howard, Nora Jaskowiak, Jennifer Tseng, Nan Chen, Olwen Hahn, Gini Fleming, Dezheng Huo, Rita Nanda> ;Breast Cancer Research and Treatment. 2023 Jul 1
• 12 citations
  Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer.
  Fangyuan Zhao, Minoru Miyashita, Masaya Hattori, Toshio Yoshimatsu, Frederick Howard, Kristiyana Kaneva, Ryan Jones, Joshua S K Bell, Gini F Fleming, Nora Jaskowiak, R...> ;JAMA Network Open. 2023 Mar 1
• 37 citations
  Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
  Daniel S Peiffer, Fangyuan Zhao, Nan Chen, Olwen M Hahn, Rita Nanda, Olufunmilayo I Olopade, Dezheng Huo, Frederick M Howard> ;JAMA Oncology. 2023 Apr 1
• 28 citations
  Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
  Susana Garcia-Recio, Toshinori Hinoue, Gregory L Wheeler, Benjamin J Kelly, Ana C Garrido-Castro, Tomas Pascual, Aguirre A De Cubas, Youli Xia, Brooke M Felsheim, Marn...> ;Nature Cancer. 2023 Jan 1
• 4 citations
  Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.
  Kala Visvanathan, Leslie Cope, Mary Jo Fackler, Michael Considine, Lori Sokoll, Lisa A Carey, Andres Forero-Torres, James N Ingle, Nancy U Lin, Rita Nanda, Anna Maria ...> ;Clinical Cancer Research. 2023 Feb 16
• 7 citations
  Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
  Elias, A., Julie E Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A Parker, A Jo Chien, Anne M Wallace, Rashmi Murthy, Kathy S...> ;NPJ Breast Cancer. 2022 Dec 1
• 1 citations
  The evolving therapeutic landscape of antibody-drug conjugates in breast cancer.
  Nan Chen, Elena Michaels, Frederick Howard, Rita Nanda> ;Expert Review of Anticancer Therapy. 2022 Dec 1
• 2 citations
  GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
  Hope S Rugo, Javier Cortes, Carlos H Barrios, Paula Cabrera, Binghe Xu, Chiun-Sheng Huang, Sung-Bae Kim, Michelle Melisko, Rita Nanda, Tadeusz Pieńkowski, Bernardo L R...> ;Future Oncology. 2022 Oct 21
• 7 citations
  Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.
  Wen Li, Nu N Le, Natsuko Onishi, David C Newitt, Lisa J Wilmes, Jessica E Gibbs, Julia Carmona-Bozo, Jiachao Liang, Savannah C Partridge, Elissa R Price, Bonnie N Joe,...> ;Cancers. 2022 Sep 13
• 3 citations
  Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform.
  Frederick M Howard, Gong He, Joseph R Peterson, J R Pfeiffer, Tyler Earnest, Alexander T Pearson, Hiroyuki Abe, John A Cole, Rita Nanda> ;Breast Cancer Research and Treatment. 2022 Nov 1
• 19 citations
  Clinical trials of immunotherapy in triple-negative breast cancer.
  Frederick M Howard, Alexander T Pearson, Rita Nanda> ;Breast Cancer Research and Treatment. 2022 Aug 1
• 9 citations
  Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer tri...
  M Marczyk, A Mrukwa, C Yau, D Wolf, Y-Y Chen, R Balassanian, R Nanda, B A Parker, G Krings, H Sattar, J C Zeck, K S Albain, J C Boughey, M C Liu, A D Elias, A S Clark,...> ;Annals of Oncology. 2022 Aug 1
• 4 citations
  Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy.
  Zhen Ren, Federico D Pineda, Frederick M Howard, Elle Hill, Teodora Szasz, Rabia Safi, Milica Medved, Rita Nanda, Thomas E Yankeelov, Hiroyuki Abe, Gregory S Karczmar> ;Academic Radiology. 2022 Oct 1
• 8 citations
  Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TB...
  Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani...> ;NPJ Breast Cancer. 2022 Feb 16
• 13 citations
  BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breas...
  Bryan P Schneider, Guanglong Jiang, Tarah J Ballinger, Fei Shen, Christopher Chitambar, Rita Nanda, Carla Falkson, Filipa C Lynce, Christopher Gallagher, Claudine Isaa...> ;Journal of Clinical Oncology. 2022 Feb 1
• 34 citations
  Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
  Elias, A., Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van't Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudin...> ;Nature Communications. 2021 Nov 5
• 12 citations
  Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
  Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kath...> ;NPJ Breast Cancer. 2021 Oct 5
• 12 citations
  The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.
  Frederick M Howard, Dario Villamar, Gong He, Alexander T. Pearson, Rita Nanda> ;Expert Opinion on Investigational Drugs. 2021 Oct 11
• 38 citations
  Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clini...
  W. Fraser Symmans, Christina Yau, Yunn Yi Chen, Ronald Balassanian, Molly Klein, Lajos Pusztai, Rita Nanda, Barbara A. Parker, Brian Datnow, Gregor Krings, Shi Wei, Mi...> ;JAMA Oncology. 2021 Sep 16
• 42 citations
  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
  Leisha A. Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L. Disis, Margaret E. Gatti-Mays, Alice Y. Ho, Kevin Kalinsky, Heather L. McArthur, Elizabeth A. Mittendorf,...> ;Journal for Immunotherapy of Cancer. 2021 Aug 1
• Join now to see all

Journal Articles

• Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer  
  Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology
• Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study  
  M C Liu, R Nanda, H S Rugo, E P Winer, S Adams, Annals of Oncology
• Immune Checkpoint Inhibition for Triple-Negative Breast Cancer  
  Saha P and Nanda R, Oncology and Hematology Review, 1/8/2016
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase 1b KEYNOTE-012 Study  
  Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L, J Clin Oncol, 1/2/2016
• Significance of Circulating Tumor Cells in metastatic triple negative breast cancer patients within a randomized, phase II trial: TBCRC 019  
  Paoletti C, Li Y, Muniz MC, Kidwell KM, Aung K, Thomas DG, Brown M, Abramson V, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, V..., Clin Cancer Res, 1/16/2015
• TBCRC 019: phase II trial of nab-PAC with/without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple negative breast cancer  
  Forero-Torres A, Varley KE, Abramson V, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Stroniolo AM, Traina TA, Patil S, Van Poznak C, Nangia JR, Irvin WJ Jr, Hel..., Clin Cancer Res, 1/16/2015
• Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Seconda...  
  McGuire KP, Hwang ES, Cantor A, Golshan M, Meric-Bernstam F, Horton JK, Nanda R, Amos KD, Forero A, Hudis CA, Meszoely I, De Los Santos JF, Ann Surg Oncol, 1/1/2015
• The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer  
  DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, ..., Clin Cancer Res, 1/1/2015
• TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases  
  Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, ..., Breast Cancer Res Treat, 1/8/2014
• Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment  
  Maranville JC, Nanda R, Fleming GF, Skor MN, Di Rienzo A, Conzen SD, Pharmacogenet Genomics, 1/3/2014
• Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017)  
  J De Los Santos, Jennifer, A Cantor, K Amos, A Forero, M Golshan, J Horton, C Hudis, N Hylton, K McGuire, F Meric-Bernstam, I Meszoely, R Nanda, S Hwang, Cancer, 1/15/2013
• TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy, and without chemotherapy in patients with HER2 overexpressing b...  
  MF Rimawi, IA Mayer, A Forero, R Nanda, MP Goetz, AA Rodriguez, AC Pavlick, T Wang, SG Hilsenbeck, C Gutierrez, R Schiff, CK Osborne, JC Chang, J Clin Oncol, 1/10/2013
• A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastaticbreast cancer  
  Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF, Breast Cancer Res Treat, 1/1/2013
• The role of tumor-associated macrophages in breast cancer progression  
  Obeid E, Nanda R, Fu YX, Olopade OI, Int J Oncol, 1/1/2013
• Phase II Trial of Temsirolimus in Patients with Metastatic Breast Cancer  
  Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade O, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ, Breast Cancer Res Treat, 1/1/2012
• “Targeting” triple-negative breast cancer: The lessons learned from BRCA1-associated breast cancers  
  Nanda R, Seminars in Oncology, 1/1/2011
• Population Differences in Breast Cancer: Survey in Indigenous African Women Reveal Overrepresentation of Triple Negative Breast Cancer  
  Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Per..., JCO, 1/24/2009
• Advances in Breast Cancer: Pathways to Personalized Medicine  
  Olopade OI, Grushko TA, Nanda R, Huo D, CCR, 1/15/2008
• Promoter methylation of Estrogen Receptor, BRCA1 and FANCF in Sporadic Breast Cancers  
  Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, Grushko TA, Olopade OI, Breast Cancer Research Treatment, 1/12/2007
• Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions  
  Nanda R, RRCT, 1/1/2007
• A New Breast Tumor Intrinsic Gene List Identifies Novel Characteristics that are Conserved Across Microarray Platforms  
  Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M,..., BMC Genomics, 1/27/2006
• A Common Pattern of Promoter Hypermethylation in Lung and Breast Tumors  
  Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euh..., PLoS Medicine, 1/1/2006
• Genetic testing in an Ethnically Diverse Cohort of High Risk Women: A Comparative Analysis of BRCA1 and BRCA2 Mutations in American Families of European and African A...  
  Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI, JAMA, 1/19/2005
• BRCA1 Promoter Methylation in Sporadic Breast Cancer is Associated with Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy  
  Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI, Cancer Research, 1/1/2005
• Join now to see all

Books/Book Chapters

• Cancer Biology Review: A Case Based Approach 
  Chapter: Fundamental of DNA Damage and Repair 
  P Connell and R NandaEditors: W Stadler.Edition 1st,2013
• Cancer Medicine 
  Chapter: Recurring Chromosome Rearrangements in Human Cancer 
  DA Levitan, R Nanda, JD Rowley, OI OlopadeEditors: J Holland and E Frei.Edition 6th,2003
• Pocket Primary Care 
  Chapter: Chronic Fatigue Syndrome 
  Nanda REditors: LK Halasyamani and BP Lucas.Edition 1st,2001

Lectures

• Immunotherapy for the Treatment of Triple-Negative Breast Cancer 
  Royal College of Physicians, London, United Kingdom - 1/1/2016
• Immunotherapy in Oncology 
  Cancun, Mexico - 1/1/2016
• Advances in Triple-Negative Breast Cancer 
  Cancun, Mexico - 1/1/2016
• “Targeting” triple-negative breast cancer 
  Dyer, IN, 2015; New Haven, CT, 2015 - 1/1/2015
• Neoadjuvant clinical trials for breast cancer 
  1/1/2015
• Breast Cancer Updates 
  Chicago, IL - 1/1/2015
• Neoadjuvant Chemotherapy for Breast Cancer 
  Chicago, IL - 1/1/2015
• Neoadjuvant and Adjuvant Therapy and the Treatment of Early Stage Breast Cancer 
  Omaha, NE - 1/1/2015
• Immunotherapy for Breast Cancer—Hype or Hope? 
  Huntington Beach, CA - 1/1/2015
• Immunotherapy for Breast Cancer 
  Chicago, IL, 2015; San Francisco, CA, 2015; Naples, Italy, 2015 - 1/1/2015
• Neoadjuvant chemotherapy for triple-negative breast cancer 
  1/1/2014
• A Phase Ib Study of Pembrolizumab (MK-3475) in Patients With Advanced Triple-Negative Breast Cancer 
  San Antonio, TX - 1/1/2014
• A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (nab-paclitaxel, Abraxane®) With or Without Mifepristone for Advanced Breast Cancer 
  1/1/2013
• Neoadjuvant chemotherapy in the very young patient 
  1/1/2013
• Case Studies in HER-2 Positive Breast Cancer 
  1/1/2013
• Genetics and Breast Cancer: Risk Assessment and Genetic Testing 
  Bellevue, WA - 1/1/2013
• The alternatively activated macrophage phenotype correlates with aggressive histopathologic features and poor clinical outcome in early stage breast cancer 
  Buonas, Switzerland - 1/1/2013
• A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (Abraxane®) With or Without Mifepristone for Advanced Breast Cancer 
  San Antonio, TX - 1/1/2013
• Neoadjuvant chemotherapy for HER2 positive breast cancer 
  1/1/2012
• Breast Cancer 
  1/1/2012
• Neoadjuvant Chemotherapy 
  1/1/2012
• Triple-negative metastatic breast cancer 
  Chicago, IL - 1/1/2012
• Breast Cancer Clinical Updates from the Best of ASCO 
  1/1/2011
• Tumor-associated macrophages and breast cancer 
  1/1/2010
• T regulatory cells are associated with the M2/alternatively activated macrophage phenotype and the basal-like breast cancer subtype 
  Washington, DC - 1/1/2010
• Join now to see all

Other

• Immunotherapy for triple-negative breast cancer 
  Numerous Outlets
  1/1/2016
• Interview on the role of clinical trials for breast cancer 
  WebMD
  1/1/2013
• Interview on treatment and research for breast cancer 
  ABC 7 News
  1/1/2012
• Interview on triple-negative breast cancer 
  CBS Chicago News
  1/1/2011
• Interview on HER2 positive metastatic breast cancer 
  Chicago Sun Times
  1/1/2011
• The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with muta... 
  Nanda R and Olopade OI, Breast Diseases: A yearbook
  1/1/2003
• Join now to see all